Tag archive for ‘methylated MGMT’
ImmunoCellular Therapeutics LTD: Thoughts on Management’s Plan to Move ICT-107 into Phase 3 (IMUC, Neutral, $1.02)
Investment Overview ImmunoCellular and its dendritic cell cancer vaccine ICT-107 were written off as failures in December of 2013 after it was announced that the phase 2 trial in newly diagnosed glioblastoma multiforme (GBM) failed to reach statistical significance on the primary endpoint of median overall survival. However, I believe IMUC is putting forward a […]